Market Research Reports and Industry Reports

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Albireo Pharma Inc (Albireo), formerly Biodel Inc., is a specialty biopharmaceutical company that focuses on the development and commercialization of innovative bile acid modulators for the treatment of orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe medical conditions for which there is high unmet need. The companys lead product candidate, A4250 is a novel, minimally absorbed, orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor. The product is in a Phase II clinical trial for progressive familial intrahepatic cholestasis (PFIC), a rare, life-threatening genetic disorder affecting young children and potentially other orphan pediatric liver diseases. Albireo is located in Boston, Massachusetts, the US.

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Albireo Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Albireo to Raise USD10 Million in Venture Financing 12
Partnerships 13
Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13
Merger 14
Biodel and Albireo Merges 14
Licensing Agreements 16
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16
Biodel Enters Into Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17
Equity Offering 18
Albireo Pharma Files Prospectus to Raise up to USD125 Million in Public Offering 18
Albireo Pharma Raises USD52 Million in Public Offering of Shares 20
Biodel Raises USD34.5 Million in Public Offering of Shares 22
Biodel to Raise up to USD15 Million in Private Placement of Shares 24
Biodel Completes Public Offering Of Shares For US$20.5 Million 26
Biodel Completes Private Placement Of Units For US$18.5 Million 27
Biodel Completes Private Placement Of US$30 Million 28
Albireo Pharma Inc - Key Competitors 30
Albireo Pharma Inc - Key Employees 31
Albireo Pharma Inc - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 14, 2017: Albireo Reports Third Quarter 2017 Financial Results 33
Aug 21, 2017: Albireo Reports Second Quarter 2017 Financial Results 35
May 10, 2017: Albireo Reports First Quarter 2017 Financial Results 37
Mar 14, 2017: Albireo Reports 2016 Financial Results 39
Aug 11, 2016: Biodel Reports Third Quarter Fiscal Year 2016 Financial Results 41
May 09, 2016: Biodel Reports Second Quarter Fiscal Year 2016 Financial Results 42
Feb 16, 2016: Biodel Reports First Quarter Fiscal Year 2016 Financial Results 43
Corporate Communications 44
Sep 28, 2017: Albireo Elects Roger Jeffs to Board of Directors 44
Jan 29, 2016: Biodel Announces Restructuring Update 45
Product Approvals 46
Nov 15, 2016: Albireos Lead Product Candidate for Orphan Pediatric Liver Disease Accepted Into European Medicines Agencys PRIME Program 46
Clinical Trials 47
Oct 03, 2016: Albireo Announces Positive Top-Line Phase 3 Results for Elobixibat in Japan 47
Sep 30, 2016: EA Pharma and Mochida Pharmaceutical Announce the Results of Phase 3 Study of AJG533 for Chronic Constipation Conducted in Japan 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List Of Tables

List of Tables
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Albireo Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Albireo Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Albireo Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Albireo to Raise USD10 Million in Venture Financing 12
Biodel Enters Into Co-Development Agreement With Yichang Chang Jiang Pharma 13
Biodel and Albireo Merges 14
Ajinomoto Pharma Amends Licensing Agreement with Albireo for Elobixibat 16
Biodel Enters Into Licensing Agreement With Aegis Therapeutics For ProTek And Intravail Technologies 17
Albireo Pharma Files Prospectus to Raise up to USD125 Million in Public Offering 18
Albireo Pharma Raises USD52 Million in Public Offering of Shares 20
Biodel Raises USD34.5 Million in Public Offering of Shares 22
Biodel to Raise up to USD15 Million in Private Placement of Shares 24
Biodel Completes Public Offering Of Shares For US$20.5 Million 26
Biodel Completes Private Placement Of Units For US$18.5 Million 27
Biodel Completes Private Placement Of US$30 Million 28
Albireo Pharma Inc, Key Competitors 30
Albireo Pharma Inc, Key Employees 31
Albireo Pharma Inc, Other Locations 32
Albireo Pharma Inc, Subsidiaries 32

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Albireo Pharma Inc (Albireo), formerly Biodel Inc., is a specialty biopharmaceutical company that focuses on the development and commercialization of innovative bile acid modulators for the treatment of orphan pediatric

USD 250View Report

Albireo Pharma Inc (ALBO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Albireo Pharma Inc (Albireo), formerly Biodel Inc., is a specialty biopharmaceutical company that focuses on the development and commercialization of innovative bile acid modulators for the treatment of orphan pediatric

USD 250View Report

AzurRx BioPharma Inc (AZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that carries out the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The

USD 250View Report

Valeo Pharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Valeo Pharma Inc (Valeo Pharma), a subsidiary of Manitex Capital Inc is a pharmaceutical company which provides healthcare solutions and specialty products. The company offers dermatology products which include drops,

USD 250View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Dec 2017
No. of Pages :49
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube